A patient's psychological factors, such as optimism, empathy, anxiety, and catastrophizing of pain can influence placebo effects [2, 9] . Due to the increased use of placebos in randomized clinical trials [11] , it is important to consider other factors that can alter the placebo response. In a recent study, beliefs pertaining to expectation biases, body consciousness, and baseline symptom severity were found to be predictive for placebo response [6] . The physicianpatient relationship can also influence the magnitude of the placebo effect. For example, a competent clinician with a warm and genuine demeanor towards the patient can influence the effectiveness of a placebo [7] . But to what degree? Knowing how much a placebo effect can diminish a patient's pain severity, if at all, is critically important as we consider the results of the research we read; for example, the magnitude of the placebo effect is a critically important consideration when reading case series (Level-IV studies of treatments) in orthopaedic journals, and of course it is an essential piece of information when considering effect sizes so as to correctly determine sample size when conducting controlled trials under the supervision of an Institutional Review Board. Deciding whether placebos should be used as a therapeutic intervention in practice, of course, is a great deal more complicated [8] .
In the current study, Crijns and colleagues [3] examine the psychological factors associated with decreased disability and pain intensity after placebo injections for the treatment of painful nontraumatic upper extremity conditions. They also investigated the psychological factors associated with achieving a minimum clinically important difference in disability and pain intensity for those treated with placebo intervention. The authors surprisingly found that psychological factors have little influence over the placebo effect; decreased pain intensity and disability was not related to placebo effect.
Where Do We Need To Go?
One of the challenges for researchers interested in this topic is to identify those factors that are associated with differences in pain intensity after exposure to a placebo treatment, particularly those factors that have a large impact on this important parameter. Certainly, anxiety, depression, and catastrophizing seem likely to be on that list, and the fact that they were not identified as such in the current study is an interesting and potentially important finding that future studies should seek to replicate. Heterogeneity in published studies and questions about the effect of age [1] , sex [4] and even patient genetics [5] I believe the exploration of placebos as potential therapeutic interventions deserves more attention. Randomized trials that specifically focus on clinically important effect sizes for key endpoints like pain and disability will be essential, as well as the ability to predict the effect and placebo response need cohort studies. As essential are the important ethical conversations that will need to accompany our decisions about whether and when it may be appropriate to use placebo treatments in practice, as this is both complicated and controversial [8] .
Observational studies-such as the current one that used the placebo arm of prior randomized trials, or retrospective studies of other designs-may also be helpful, but probably less so than prospective (and ideally, randomized) trials that focus specific on these important topics. Studies that focus on the nature of the illness and how the severity of pain can influence the placebo effect may be more fruitful.
